FANCL Corp. engages in the manufacture and sale of cosmetics and nutritional supplements. It operates through the following segments: Cosmetics, Nutritional Supplements, and Others. The Cosmetics segment deals with manufacture and sale of cosmetics and provides original equipment manufacturer products. The Nutritional Supplements segment handles manufacture and sale of food supplements. The Others segment includes online sales of undergarments, health equipment, and lifestyle products. It also offers germinated brown rice, kale juice, and esthetic business. The company was founded by Kenji Ikemori in April 1980 and is headquartered in Yokohama, Japan.

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. Its products include original medicine such as Chidamide, Chiglitazar, Chiauranib. It also engages in technological licensing. The company was founded by Xian Ping Lu and Zhi Qiang Ning on March 21, 2001 and is headquartered in Shenzhen, China.

Alterity Therapeutics has developed a proprietary library of class-leading chemical compounds. This library is combined with a drug development program to explore novel therapeutics in multiple disease indications. The scientific focus of the company is upon neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Founded in 2006 and headquartered in West Palm Beach, Florida, Xcovery is comprised of an experienced team that is dedicated to advancing next generation targeted therapeutics as promising new treatments to improve the lives of cancer patients. Xcovery’s mission is to develop low toxicity molecular targeted oral drugs which will allow continuous therapy and will not require dosing “holidays”. Low toxicity will allow a greater “therapeutic window” and the ability to more effectively treat multiple cancers with higher potency. Low toxicity will also allow our drugs to better be used in combination therapy where other, current therapies, are too toxic to be effective. Our Team Xcovery’s CEO, Sheridan Snyder, is a veteran entrepreneur who began his biotech career in 1981 when he founded Genzyme, followed by Biotage, Upstate Biotechnology and now Xcovery and Tyrogenex. Mr. Snyder has funded Xcovery’s first 5 years of development, through his personal investment vehicle, BioCatalyst International, Inc. This is consistent with his “formula” for developing more than 14 start-ups over a 40 year period, all of which are operating successfully today. Xcovery’s Chief Scientific Officer, Dr. Chris Liang, served as Director, Medicinal Chemistry at SUGEN (acquired by Pfizer in 2003) where he developed Sutent®, an FDA approved VEGFR/PDGFR angiogenesis inhibitor for the treatment of kidney cancer and second-line gastrointestinal cancer in Gleevec-resistant patients. The result of his knowledge, extensive experience and a unique set of medicinal chemistry design tools have enabled Xcovery to create a broad portfolio of kinase inhibitors. Xcovery’s Vice President, Oncology, Dr. Jay Gibbons, brings more than 25 years of oncology research and management experience to the team with a strong emphasis on translational medicine. During his previous role as AVP, Oncology Research at Wyeth, he was instrumental in filing eight IND’s and the NDA for Torisel® (temsirolimus), currently approved for the treatment of renal cell carcinoma.

NewGen Therapeutics, Inc. engages in the provision of research and development services. The company is headquartered in Menlo Park, CA.

Sugen is a biotechnology company that specializes in target-driven drug discovery and development for novel development-stage cancer therapies. It develops new therapeutic approaches to various diseases through its development of small molecule inhibitors that regulate particular signaling pathways. Sugen owns three anti-cancer drugs in clinical development, including novel cytostatic agents and angiogenesis inhibitors. In addition to its current focus in oncology, Sugen is applying its technology platform to identify and validate novel targets for a range of potential clinical applications.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Axonyx, Inc. is an biopharmaceutical company, which manufactures medical products and technologies to treat Alzheimer's disease and other Central Nervous System disorders. It is located in New York, NY.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Part of OPKO Health, Inc., Waratah Pharmaceuticals, Inc. is a company headquartered in Calgary, AB, Canada, that develops pharmaceutical products. The firm was founded by Susan Dana Jones. Transition Therapeutics, Inc., a subsidiary of OPKO Health, Inc. since September 2016, acquired Waratah Pharmaceuticals, Inc. on January 28, 2002 for $15.46 million.

Plexxikon, Inc. engages in the discovery and development of small molecule pharmaceuticals to treat human disease. The company's products include PLX204 for the treatment of diabetes; PLX4032 for the treatment of melanoma and colorectal cancer; and PLX5568 kinase inhibitors for the treatment of pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. It develops a portfolio of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, such as obesity indications; oncology, such as osteolytic metastatic disease; and CNS, such as multiple sclerosis. The company’s portfolio of clinical and preclinical stage programs for other therapeutic areas include inflammation, such as systemic lupus erythematosus, inflammatory bowel disease, and osteoporosis; and cardiovascular, including hypertension and atherosclerosis.

Assistance Publique H��pitaux de Marseille is a private company headquartered in Marseille, France, specializing in general medical and surgical hospitals.

Asahi Kasei Medical Co. Ltd. engages in the development, manufacture and sale of medical devices. It also engages in the development, manufacture and sale of dialyzers, therapeutic apheresis products, leukocyte reduction filters and virus removal filters. The company was founded on July 24, 1974 and is headquartered in Tokyo, Japan.

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

The Georgia Tech Research Corp. provides research and technology support services. Its services include accounting and reports, researcher and operational support services. The comapny was founded by Preston S. Arkwright, Fuller E. Callaway, Jr. and Monie A. Ferst on April 13, 1937 and is headquartered in Atlanta, GA.